Distinguished in Embryonal Tumor with Multilayered Rosettes

Dr. Maryam Fouladi

Pediatric Hematology Oncology
536 S Trimble Rd, 
Mansfield, OH 
Clinical Trials:Currently Recruiting for 1 Trial
Distinguished in Embryonal Tumor with Multilayered Rosettes
536 S Trimble Rd, 
Mansfield, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Maryam Fouladi is a Pediatric Hematologist Oncology provider in Mansfield, Ohio. Dr. Fouladi is rated as a Distinguished provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. Her top areas of expertise are Diffuse Midline Glioma H3 K27M-Mutant, Glioma, Medulloblastoma, and Brain Stem Cancer.

Her clinical research consists of co-authoring 154 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 28 articles and participated in 5 clinical trials in the study of Embryonal Tumor with Multilayered Rosettes.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatric Hematology-Oncology in OH
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 1 Less Insurance Carrier -

Locations

536 S Trimble Rd, Mansfield, OH 44906
Other Locations
700 Childrens Dr, Columbus, OH 43205
4439 State Route 159, Chillicothe, OH 45601
5665 Venture Dr, Dublin, OH 43017
6435 E Broad St, Columbus, OH 43213
740 Adair Ave, Zanesville, OH 43701
7853 Pacer Dr, Delaware, OH 43015

Additional Areas of Focus

Dr. Fouladi has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)
Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

Phase 2 Study of the MEK Inhibitor MEKTOVI® (Binimetinib) for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
Phase 2 Study of the MEK Inhibitor MEKTOVI® (Binimetinib) for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
Enrollment Status: Recruiting
Publish Date: June 11, 2025
Intervention Type: Drug
Study Phase: Phase 2
Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects With Recurrent/Refractory Brain Tumors and Newly Diagnosed Brain Stem Glioma
Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects With Recurrent/Refractory Brain Tumors and Newly Diagnosed Brain Stem Glioma
Enrollment Status: Active_not_recruiting
Publish Date: September 29, 2025
Intervention Type: Biological
Study Drug: APX005M
Study Phase: Phase 1
A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations
A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2025
Intervention Type: Drug, Radiation
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2
A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)
A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)
Enrollment Status: Active_not_recruiting
Publish Date: September 18, 2025
Intervention Type: Procedure, Radiation, Drug
Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 2
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Enrollment Status: Active_not_recruiting
Publish Date: August 12, 2025
Intervention Type: Drug, Procedure, Radiation, Other
Study Drugs: Cisplatin, Cyclophosphamide, Lomustine, Vincristine, Vincristine Sulfate
Study Phase: Phase 2
A Safety and Preliminary Efficacy Trial of Pembrolizumab (MK-3475) in Children With Recurrent, Progressive or Refractory Diffuse Intrinsic Pontine Glioma (DIPG), Non-Brainstem High-Grade Gliomas (NB-HGG), Ependymoma, Medulloblastoma or Hypermutated Brain Tumors
A Safety and Preliminary Efficacy Trial of Pembrolizumab (MK-3475) in Children With Recurrent, Progressive or Refractory Diffuse Intrinsic Pontine Glioma (DIPG), Non-Brainstem High-Grade Gliomas (NB-HGG), Ependymoma, Medulloblastoma or Hypermutated Brain Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 01, 2025
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 1
Single-arm, Multicenter Phase I/Ib Study of Avelumab + Lenvatinib in Children With Primary CNS Tumors
Single-arm, Multicenter Phase I/Ib Study of Avelumab + Lenvatinib in Children With Primary CNS Tumors
Enrollment Status: Active_not_recruiting
Publish Date: July 20, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma
A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma
Enrollment Status: Active_not_recruiting
Publish Date: February 24, 2025
Intervention Type: Radiation, Drug
Study Drug: PTC596
Study Phase: Phase 1
ONC201 in Newly Diagnosed Diffuse Intrinsic Pontine Glioma and Recurrent/Refractory Pediatric H3 K27M Gliomas
ONC201 in Newly Diagnosed Diffuse Intrinsic Pontine Glioma and Recurrent/Refractory Pediatric H3 K27M Gliomas
Enrollment Status: Terminated
Publish Date: February 14, 2025
Intervention Type: Drug
Study Drug: ONC201
Study Phase: Phase 1
Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine (HCQ) for BRAF V600E-mutant or Trametinib and HCQ for BRAF Fusion/Duplication Positive or NF1-associated Recurrent or Progressive Gliomas in Children and Young Adults
Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine (HCQ) for BRAF V600E-mutant or Trametinib and HCQ for BRAF Fusion/Duplication Positive or NF1-associated Recurrent or Progressive Gliomas in Children and Young Adults
Enrollment Status: Active_not_recruiting
Publish Date: February 04, 2025
Intervention Type: Drug
Study Drugs: Dabrafenib, Trametinib, Hydroxychloroquine
Study Phase: Phase 1/Phase 2
A Phase 1 Open Label, Multi-Center Study to Evaluate the Safety and Tolerability of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) and Diffuse Midline Glioma (DMG)
A Phase 1 Open Label, Multi-Center Study to Evaluate the Safety and Tolerability of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) and Diffuse Midline Glioma (DMG)
Enrollment Status: Terminated
Publish Date: December 20, 2024
Intervention Type: Drug
Study Drug: BXQ-350
Study Phase: Phase 1
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
Enrollment Status: Active_not_recruiting
Publish Date: October 26, 2024
Intervention Type: Drug, Radiation, Biological, Other
Study Drugs: Carboplatin, Cisplatin, Cyclophosphamide, Etoposide, Vincristine
Study Phase: Phase 3
A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
Enrollment Status: Completed
Publish Date: October 03, 2024
Intervention Type: Drug
Study Drug: Tazemetostat
Study Phase: Phase 1
Phase 1 Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma
Phase 1 Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma
Enrollment Status: Completed
Publish Date: April 25, 2024
Intervention Type: Drug
Study Drug: LBH589
Study Phase: Phase 1
A Phase I and Surgical Study of Ribociclib and Everolimus (RAD001) in Children With Recurrent or Refractory Malignant Brain Tumors
A Phase I and Surgical Study of Ribociclib and Everolimus (RAD001) in Children With Recurrent or Refractory Malignant Brain Tumors
Enrollment Status: Completed
Publish Date: August 27, 2021
Intervention Type: Other, Drug
Study Phase: Phase 1
Phase I Study of CDK 4-6 Inhibitor PD-0332991 (Palbociclib; IBRANCE) in Children With Recurrent, Progressive or Refractory Central Nervous System Tumors
Phase I Study of CDK 4-6 Inhibitor PD-0332991 (Palbociclib; IBRANCE) in Children With Recurrent, Progressive or Refractory Central Nervous System Tumors
Enrollment Status: Terminated
Publish Date: March 02, 2021
Intervention Type: Other, Drug
Study Phase: Phase 1
View 15 Less Clinical Trials

154 Total Publications

IDH mutant high-grade gliomas.
IDH mutant high-grade gliomas.
Journal: Frontiers in molecular neuroscience
Published: July 09, 2025
Similar Doctors
Distinguished in Embryonal Tumor with Multilayered Rosettes
Dr. Dean A. Lee
Pediatric Hematology Oncology
Distinguished in Embryonal Tumor with Multilayered Rosettes
Dr. Dean A. Lee
Pediatric Hematology Oncology
536 S Trimble Rd, 
Mansfield, OH 
 (0.1 miles away)
614-722-6200
Languages Spoken:
English
See accepted insurances

Dean Lee is a Pediatric Hematologist Oncology provider in Mansfield, Ohio. Dr. Lee is rated as a Distinguished provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Embryonal Tumor with Multilayered Rosettes, Osteosarcoma, Neuroblastoma, Adult Soft Tissue Sarcoma, and Bone Marrow Transplant.

Distinguished in Embryonal Tumor with Multilayered Rosettes
Dr. Timothy P. Cripe
Pediatric Hematology Oncology
Distinguished in Embryonal Tumor with Multilayered Rosettes
Dr. Timothy P. Cripe
Pediatric Hematology Oncology
536 S Trimble Rd, 
Mansfield, OH 
 (0.1 miles away)
614-722-6200
Languages Spoken:
English
See accepted insurances

Timothy Cripe is a Pediatric Hematologist Oncology provider in Mansfield, Ohio. Dr. Cripe is rated as a Distinguished provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Embryonal Tumor with Multilayered Rosettes, Ewing Sarcoma, Neuroblastoma, and Osteosarcoma.

Distinguished in Embryonal Tumor with Multilayered Rosettes
Dr. Keri A. Streby
Pediatric Hematology Oncology
Distinguished in Embryonal Tumor with Multilayered Rosettes
Dr. Keri A. Streby
Pediatric Hematology Oncology
5665 Venture Dr, 
Dublin, OH 
 (54.3 miles away)
614-722-2000
Languages Spoken:
English
See accepted insurances

Keri Streby is a Pediatric Hematologist Oncology provider in Dublin, Ohio. Dr. Streby is rated as an Advanced provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. Her top areas of expertise are Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Hereditary Neuroblastoma, and Acute Lymphoblastic Leukemia (ALL).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Fouladi's expertise for a condition
ConditionClose
View All 7 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile